# A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

> **NCT07285902** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 572 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** HRS9531 injection
- **DRUG:** Semaglutide Injection

## Key facts

- **NCT ID:** NCT07285902
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-25
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285902, "A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07285902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*